Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

SHE:300009 Revenue

Anhui Anke Biotechnology (Group) had revenue of 556.18M CNY in the quarter ending June 30, 2026, a decrease of -16.17%. This brings the company's total for the last twelve months to 2.45B, down -3.05% year-over-year. In the year 2025, Anhui Anke Biotechnology (Group) had annual revenue of 2.65B with 4.36% growth. That makes Anhui Anke Biotechnology (Group) the 13,112th largest company in the world by revenue and 2,289th in China.

• Revenue (ttm): 2.45B
• Revenue Growth: -3.05%
• P/S Ratio: 5.35
• Revenue / Employee: 978.93K
• Employees: 2,505
• Market Cap: 13.07B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Biological Products 1.98B 74.8%
• Chinese Patent Medicine 289.17M 10.9%
• Synthetic drugs 150.25M 5.7%
• Active Pharmaceutical Ingredient (API) 101.58M 3.8%
• Others 100.88M 3.8%
• Technical Services 24.73M 0.9%

By Geography

Chart

• East China (Excluding Anhui) 975.33M 36.9%
• Central and Southwest China 652.18M 24.6%
• South China 337.40M 12.7%
• North China, Northeast Region 325.16M 12.3%
• Anhui 237.49M 9.0%
• Northwest China 115.25M 4.4%
• Unallocated 3.19M 0.1%
• Overseas 513.03K 0.0%

Fiscal year ended Dec 31, 2025 See the full SHE:300009 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.65B	110.48M	4.36%
Dec 31, 2024	2.54B	-329.71M	-11.51%
Dec 31, 2023	2.87B	534.69M	22.94%
Jan 1, 2023	2.33B	162.30M	7.48%
Dec 31, 2021	2.17B	467.35M	27.47%

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error